Venetoclax treatment in cancer patients has limited impact on circulating T and NK cells.
Sign Up to like & getrecommendations! Published in 2022 at "Blood advances"
DOI: 10.1182/bloodadvances.2022008221
Abstract: Venetoclax is an effective treatment for certain blood cancers, such as chronic lymphocytic leukemia (CLL) and acute myeloid leukemia (AML). However, most patients relapse while on venetoclax and further treatment options become limited. Combining venetoclax… read more here.
Keywords: impact circulating; cancer patients; circulating cells; venetoclax treatment ... See more keywords
The impact of circulating IGF-1 and IGFBP-2 on cardiovascular prognosis in patients with acute coronary syndrome
Sign Up to like & getrecommendations! Published in 2023 at "Frontiers in Cardiovascular Medicine"
DOI: 10.3389/fcvm.2023.1126093
Abstract: Background While insulin-like growth factor 1 (IGF-1) exerts a cardioprotective effect in the setting of atherosclerosis, insulin-like growth factor binding protein 2 (IGFBP-2) is involved in metabolic syndrome. Although IGF-1 and IGFBP-2 are known to… read more here.
Keywords: igf igfbp; coronary syndrome; igfbp levels; acute coronary ... See more keywords